Acute Intravenous Injection of Serelaxin (Recombinant Human Relaxin‐2) Causes Rapid and Sustained Bradykinin‐Mediated Vasorelaxation

BACKGROUND: A recent clinical trial (RELAXin in Acute Heart Failure [RELAX‐AHF]) demonstrated that 48 hours of continuous intravenous infusion of the vasorelaxant peptide serelaxin (recombinant human relaxin‐2) to patients with acute heart failure reduced cardiovascular mortality at 180 days. The pe...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Leo, Chen Huei, Jelinic, Maria, Parkington, Helena C., Tare, Marianne, Parry, Laura J.
Формат: Artigo
Язык:Inglês
Опубликовано: Blackwell Publishing Ltd 2014
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3959707/
https://ncbi.nlm.nih.gov/pubmed/24584737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.113.000493
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы